QDEL - Quidel more quick diagnosis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis

QDEL 24.35

+14.3%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jad who wrote (651)	4/19/1997 4:05:00 PM
From: Robert Busse	of 1693

Cleary,Gull report of 4-3-97 rates Qdel as a "#1-Buy" with a 12 month price target of 6-9 dollars per share w/ a "single point objective of 7". 24 month price target of 8-10 w/ a "single point objective " of 9. Also predicts "3-5 yr.EPS Growth" of 40%". Report states these valuations do not include any other products currently in Qdel's R + D pipeline such as the Bayer agreement "which could begin to generate product sales in the latter half of FY 98". That's this year folks!! Report also says that "Quidel will manufacture the immunoassay tests that will be marketed by BAYER under the CLINITEK brand name. Quidel's development costs will be largely finded by Bayer and sales to Bayer could begin in the second half of fiscal 1998. We believe that the agreement w/ Bayer has excellent potential to increase earnings over the long term because Quidel should realize operating leverage from the incremental sales." SAFEPLAN isn't even mentioned in the report. Predicts sale of flu test will begin in 2000. This is great report-now if we could only get this pesky lawsuit resolved!!! BOB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next